Skip to main content
Premium Trial:

Request an Annual Quote

Accelerate Dx Lands CE Mark for ID/AST System, Initiates Clinical Trial Enrollment

NEW YORK (GenomeWeb) – Accelerate Diagnostics today announced it has received the CE-IVD mark for its Accelerate ID/AST System and ID/AST Blood Culture Assay and has begun enrolling trial sites for a preclinical study.

The Accelerate platform uses proprietary single-cell microbiology analysis technology to rapidly identify pathogens and provide information on their antibiotic susceptibility for clinical diagnosis.

The firm said in a statement that it has also initiated enrollment for its clinical trial for the platform in preparation for a 510(k) submission to the US Food and Drug Administration at eight trial sites. The firm maintained its expectation that it will launch an FDA-cleared product in the United States in the first half of 2016.

Accelerate Diagnostics CEO Lawrence Mehren said in January at the JP Morgan Healthcare Conference that the firm planned to launch the platform in Europe this year and would begin clinical trials in preparation for the 510(k) submission.

In March, Tucson, Arizona-based Accelerate received ISO 13485:2003 certification for its quality management system.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.